Sanofi unveils Phase 3 trial results of isatuximab combination therapy
Category: #health  By Mateen Dalal  Date: 2019-06-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sanofi unveils Phase 3 trial results of isatuximab combination therapy

The French multinational pharmaceutical company Sanofi has reportedly announced crucial Phase 3 ICARIA-MM trial results which revealed that isatuximab aided with dexamethasone and pomalidomide (isatuximab combination therapy) has shown statistically substantial improvements compared to pomalidomide and dexamethasone (pom-dex) alone in patients enduring relapsed/refractory multiple myeloma (RRMM). The results were recently presented at annual meeting in Chicago at the 2019 American Society of Clinical Oncology (ASCO).

Paul Richardson, MD, clinical program leader, principal investigator, director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, reportedly stated that Isatuximab added to pomalidomide and dexamethasone has resulted in remarkable 40 percent decrease in the risk of progression or demise in comparison with pomalidomide and dexamethasone alone. The result is significant because the study included a particularly relapsed, refractory and difficult-to-treat patient population, which was highly reflecting real-world practice, he further added.

Reportedly, Isatuximab combination therapy has shown a statistically significant improvement in progression free survival, and the median progression free survival was longer in the isatuximab combination therapy arm than pom-dex alone.

Apparently, ICARIA-MM is a crucial Phase 3 open-label, randomized, multi-center study assessing isatuximab combined with pom-dex against pom-dex alone in patients enduring RRMM. Around 307 patients suffering from RRMM have been enrolled in the study at around 96 centers in 24 nations. Overall, patients were given a median of 3 prior lines of anti-myeloma treatments which includes minimum 2 sequential cycles of a proteasome inhibitor and lenalidomide given alone or in combination.

During the study, Isatuximab was dispensed via an intravenous infusion at a dose of 10mg/kg once weekly for 4 weeks and further every other week for 28-day cycles combined with pom-dex standard doses for the period of therapy.

For the record, Isatuximab is an experimental monoclonal antibody which targets a particular epitope on the CD38 receptor of a plasma cell.

 

Source link: http://hugin.info/152918/R/2245494/886977.pdf

https://www.finanznachrichten.de/nachrichten-2019-06/46854851-sanofi-phase-3-trial-of-isatuximab-combination-therapy-showed-40-reduction-in-the-risk-of-disease-progression-or-death-for-patients-with-relapsed-re-399.htm

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Dermtech signs a commercial & medicare advantage coverage agreement
Dermtech signs a commercial & medicare advantage coverage agreement
By Mateen Dalal

DermTech Inc., a San Diego based biotechnology company that is involved in precision dermatology, has recently announced signing a contract with a regional health plan to develop its gene expression based PLA (Pigmented Lesion Assay) for prior detect...

CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
By Mateen Dalal

The merger will bring two therapeutic immune-oncology platforms together Focus shall be placed over Phase 1 and Phase 2 trials of CAR-CIK and CMN-001 respectively U.S.-based bioscience firm CoImmune, Inc., announces partnership with Formula Phar...

Adverum reviews recent business progress and unveils its 2020 outlook
Adverum reviews recent business progress and unveils its 2020 outlook
By Mateen Dalal

Adverum Biotechnologies, a California based biotech company, has reportedly announced that it has examined its recent business & development progress. The company has also unveiled its outlook for 2020. Leone Patterson, president and chief execu...